Grünenthal press releases 2010

Brussels/Aachen, September 16, 2010. The European decentralised procedure (DCP) for Grünenthal’s tapentadol has been positively concluded and both Germany and Denmark have already issued the first national licences. With tapentadol existing shortcomings may be overcome as it combines strong efficacy and better tolerability compared to classical opioids due to its unique pharmacological profile which is expected to result in improved pain management.

Aachen, 06 September, 2010. Tapentadol represents a proposed new pharmacological class called MOR-NRI (mu-opioid-receptor agonist and noradrenaline-reuptake inhibitor). This is the conclusion of a pharmacological round-table conference  which is addressed by an Editorial in the European Journal of Pain.  The centrally acting analgesic, which has a unique pharmacological profile, has been developed for the relief of moderate to severe acute pain and the management of severe chronic pain in adults.

Aachen, 07.06.2010 – The Grünenthal Group (Grünenthal) announced today that it has expanded its licensing agreement with Janssen Pharmaceutica N.V. (Janssen) to register, manufacture and commercialize Tapentadol in additional regions, including selected Asia Pacific, Latin American, African, and New European countries including Turkey and Greece, under Grünenthal’s PALEXIA^® /PALEXIS^® /NUCYNTA^® trademark for both the immediate- and prolonged-release (IR /PR) formulations.

Aachen, Germany, 25 May 2010. Young scientists from across Europe can now apply for the EFIC-Grünenthal Grant 2010, one of the most highly regarded pain research grants worldwide. Provided by the European Federation of IASP chapters (EFIC) in cooperation with pharmaceutical company and pain expert Grünenthal GmbH, this grant supports young scientists in conducting innovative clinical experimental pain research projects.

Aachen, 20 May 2010. Although chronic pain affects around 20% of adults in Europe and the USA, there is substantial evidence that this debilitating condition is often inadequately treated. A group of international pain experts has now published a first commentary calling for a CHANGE in the pharmacological management of severe chronic pain.

Aachen, 19 May, 2010. Tapentadol is the first new molecular entity developed for the oral treatment of severe pain to be introduced in the market in more than 25 years. As it is distinctly different from other centrally acting analgesics it will be the first member of a proposed new pharmacological class called MOR-NRI (mu-opioid-receptor agonist and noradrenaline-reuptake inhibitor).

Aachen, 18 January 2010. Currently, chronic pain treatment is driven mainly by pain intensity and not by the underlying mechanisms. In consequence, pharmacological treatment does not always result in sufficient analgesia, as the international advisory board of CHANGE PAIN – an initiative by the German pain expert Grunenthal and strongly endorsed by the European Federation of IASP® Chapters (EFIC®) – observed.

Aachen/Germany, 11 January, 2010. The mutual recognition procedure to obtain further marketing authorisations for Versatis® in 14 additional European countries has been positively concluded. Grunenthal has sought approval for its 5% lidocaine medicated plaster for the symptomatic relief of neuropathic pain associated with previous herpes zoster infection (post-herpetic neuralgia, PHN).